Detalles de la búsqueda
1.
Different treatment strategies versus a common standard arm (CSA) in patients with newly diagnosed AML over the age of 60 years: a randomized German inter-group study.
Ann Hematol
; 102(3): 547-561, 2023 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-36695874
2.
Evolution of severe (transfusion-dependent) anaemia in myelodysplastic syndromes with 5q deletion is characterized by a macrophage-associated failure of the eythropoietic niche.
Br J Haematol
; 198(1): 114-130, 2022 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-35362549
3.
Clonal architecture in patients with myelodysplastic syndromes and double or minor complex abnormalities: Detailed analysis of clonal composition, involved abnormalities, and prognostic significance.
Genes Chromosomes Cancer
; 57(11): 547-556, 2018 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-30248204
4.
Long-term outcome of high risk patients with myelodysplastic syndromes or secondary acute myeloid leukemia receiving intensive chemotherapy.
Ann Hematol
; 97(12): 2325-2332, 2018 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-30078145
5.
Causes of death in 2877 patients with myelodysplastic syndromes.
Ann Hematol
; 95(6): 937-44, 2016 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-27025507
6.
Decitabine improves progression-free survival in older high-risk MDS patients with multiple autosomal monosomies: results of a subgroup analysis of the randomized phase III study 06011 of the EORTC Leukemia Cooperative Group and German MDS Study Group.
Ann Hematol
; 95(2): 191-9, 2016 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-26596971
7.
Frequency of del(12p) is commonly underestimated in myelodysplastic syndromes: Results from a German diagnostic study in comparison with an international control group.
Genes Chromosomes Cancer
; 54(12): 809-17, 2015 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-26355708
8.
[Leukemia research in Germany: the Competence Network Acute and Chronic Leukemias]. / Entstehung, Entwicklung und Erfolge des Kompetenznetzes Akute und Chronische Leukämien (KNL).
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz
; 59(4): 444-53, 2016 Apr.
Artículo
en Alemán
| MEDLINE | ID: mdl-26979719
9.
Validation of cytogenetic risk groups according to International Prognostic Scoring Systems by peripheral blood CD34+FISH: results from a German diagnostic study in comparison with an international control group.
Haematologica
; 100(2): 205-13, 2015 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-25344522
10.
Decitabine versus best supportive care in older patients with refractory anemia with excess blasts in transformation (RAEBt) - results of a subgroup analysis of the randomized phase III study 06011 of the EORTC Leukemia Cooperative Group and German MDS Study Group (GMDSSG).
Ann Hematol
; 94(12): 2003-13, 2015 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-26400023
11.
Specific scoring systems to predict survival of patients with high-risk myelodysplastic syndrome (MDS) and de novo acute myeloid leukemia (AML) after intensive antileukemic treatment based on results of the EORTC-GIMEMA AML-10 and intergroup CRIANT studies.
Ann Hematol
; 94(1): 23-34, 2015 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-25096636
12.
Cellularity, characteristics of hematopoietic parameters and prognosis in myelodysplastic syndromes.
Eur J Haematol
; 95(3): 181-9, 2015 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-25600827
13.
A randomized phase 3 study of lenalidomide versus placebo in RBC transfusion-dependent patients with Low-/Intermediate-1-risk myelodysplastic syndromes with del5q.
Blood
; 118(14): 3765-76, 2011 Oct 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-21753188
14.
Targeted re-sequencing analysis of 25 genes commonly mutated in myeloid disorders in del(5q) myelodysplastic syndromes.
Haematologica
; 98(12): 1856-64, 2013 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-23831921
15.
Outcome of elderly patients with acute promyelocytic leukemia: results of the German Acute Myeloid Leukemia Cooperative Group.
Ann Hematol
; 92(1): 41-52, 2013 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-23090499
16.
Impaired formation of erythroblastic islands is associated with erythroid failure and poor prognosis in a significant proportion of patients with myelodysplastic syndromes.
Haematologica
; 101(5): e177-81, 2016 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-26944473
17.
Molecular subtypes of NPM1 mutations have different clinical profiles, specific patterns of accompanying molecular mutations and varying outcomes in intermediate risk acute myeloid leukemia.
Haematologica
; 101(2): e55-8, 2016 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-26471486
18.
Eligibility for clinical trials is unsatisfactory for patients with myelodysplastic syndromes, even at a tertiary referral center.
Leuk Res
; 108: 106611, 2021 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-33990002
19.
Azacitidine for treatment of patients with myelodysplastic syndromes (MDS): practical recommendations of the German MDS Study Group.
Ann Hematol
; 89(9): 841-50, 2010 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-20567826
20.
Patients with del(5q) MDS who fail to achieve sustained erythroid or cytogenetic remission after treatment with lenalidomide have an increased risk for clonal evolution and AML progression.
Ann Hematol
; 89(4): 365-74, 2010 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-19855965